Evidence map›Paper›PMID 40754682›Full record

ArticleClinical and translational medicine2025

Multi-omics integration analysis identifies INPP4B as a T-cell-specific activation suppressor.

Ting Peng, Qing Fang, Zihao Zhao, Yingjun Chang, Xiangyu Zhao, Cheng Li

Abstract read
In one paragraph

Article in Clinical and translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ting PengSchool of Life Sciences, Peking University, Beijing, China.ORCID 0000-0002-2126-1600
Qing FangSchool of Life Sciences, Peking University, Beijing, China.ORCID 0009-0003-8974-2384
Zihao ZhaoSchool of Life Sciences, Peking University, Beijing, China.
Yingjun ChangNational Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Beijing, China.
Xiangyu ZhaoNational Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Beijing, China.
Cheng LiSchool of Life Sciences, Peking University, Beijing, China.

Funding

National Key Research and Development Program of China 2021YFA1100300National Natural Science Foundation of China 32025006National Natural Science Foundation of China 32288102Postdoctoral Fellowship Program of CPSF GZC20240077
6 · The paper itself

Abstract

backgroundNaïve T cells are maintained in a quiescent state prior to activation. As inappropriate T-cell activation can lead to impaired immune tolerance and autoimmune diseases, the transition from quiescence to activation must be under strict regulation. Despite its importance, the mechanisms underlying the maintenance of the quiescent state remain incompletely understood. METHODS AND

resultsThrough multi-omics integration analysis, we reveal that INPP4B, a phosphatase of the phosphoinositide 3-kinase pathway, is highly expressed specifically in T cells and is involved in suppressing T-cell activation and maintaining quiescence. Our findings uncover that INPP4B forms a T-cell-specific chromatin interaction domain and exhibits high expression levels in quiescent T cells. Upon T-cell activation, both the chromatin interaction and expression levels of INPP4B decrease. Functional studies further confirm that INPP4B suppresses T-cell activation and effector functions. Additionally, we observe increased expression level of INPP4B in exhausted T cells within the tumour microenvironment.

conclusionThese results highlight the importance of maintaining optimal levels of INPP4B for T-cell function. Our findings suggest that INPP4B could be a potential target for enhancing the efficacy of T-cell-mediated immune responses against tumours. KEY POINTS: A comprehensive multi-omics analysis characterizes the expression patterns of INPP4B across immune populations. INPP4B exhibits a T-cell-specific expression domain and functions as a T cell activation suppressor. INPP4B is significantly upregulated in exhausted T cells within the tumour microenvironment.

Indexed as

Lymphocyte ActivationPhosphoric Monoester HydrolasesT-LymphocytesAnimalsHumansMiceMultiomicsphosphatidylinositol-3,4-bisphosphate 4-phosphatasePhosphoric Monoester HydrolasesINPP4Bmulti‐omicsT‐cell activation

Identifiers

PMID40754682
PMCPMC12318829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.